Patent · US Expired

Inhibitors of p38-&agr;kinase

US6410540B1 · kind B1 · utility

23Cited by
2References
25Claims
0Family size

Assignee

Inventors

Key dates

Filing dateAug 27, 1999
Grant dateJun 25, 2002
Priority date
Expiry dateAug 27, 2019

Classification

  • Technology area (CPC Y)Emerging Cross-Sectional Technologies
  • CPC primaryY02A50/30
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The invention is directed to methods to treat conditions mediated by p38-&agr;kinase using compounds of the formula and the pharmaceutically acceptable salts thereof, or a pharmaceutical composition thereof,whereinZ is N or CR1, R1 is a noninterfering substituent,each of X1 and X2 is a linker,Ar1 and Ar2 are identical or different, and represent optionally substituted C1-C20 hydrocarbyl residues wherein at least one of Ar1 and Ar2 is an optionally substituted aryl group, with the proviso that when X2 is CH2 or an isostere thereof, X1 is CO or an isostere thereof, and Ar2 is optionally substituted phenyl, Ar1 is other than an optionally substituted indolyl, benzimidazolyl or benzotriazolyl substituent, and wherein said optionally substituted phenyl is not an optionally substituted indolyl, benzimidazolyl, or benzotriazolyl,Y is a noninterfering substituent, wherein n is an integer from 0-4, andwherein m is an integer from 0-4 and 1 is an integer from 0-3.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.